Cargando…
MR-guided proton therapy: a review and a preview
BACKGROUND: The targeting accuracy of proton therapy (PT) for moving soft-tissue tumours is expected to greatly improve by real-time magnetic resonance imaging (MRI) guidance. The integration of MRI and PT at the treatment isocenter would offer the opportunity of combining the unparalleled soft-tiss...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260752/ https://www.ncbi.nlm.nih.gov/pubmed/32471500 http://dx.doi.org/10.1186/s13014-020-01571-x |
_version_ | 1783540384254656512 |
---|---|
author | Hoffmann, Aswin Oborn, Bradley Moteabbed, Maryam Yan, Susu Bortfeld, Thomas Knopf, Antje Fuchs, Herman Georg, Dietmar Seco, Joao Spadea, Maria Francesca Jäkel, Oliver Kurz, Christopher Parodi, Katia |
author_facet | Hoffmann, Aswin Oborn, Bradley Moteabbed, Maryam Yan, Susu Bortfeld, Thomas Knopf, Antje Fuchs, Herman Georg, Dietmar Seco, Joao Spadea, Maria Francesca Jäkel, Oliver Kurz, Christopher Parodi, Katia |
author_sort | Hoffmann, Aswin |
collection | PubMed |
description | BACKGROUND: The targeting accuracy of proton therapy (PT) for moving soft-tissue tumours is expected to greatly improve by real-time magnetic resonance imaging (MRI) guidance. The integration of MRI and PT at the treatment isocenter would offer the opportunity of combining the unparalleled soft-tissue contrast and real-time imaging capabilities of MRI with the most conformal dose distribution and best dose steering capability provided by modern PT. However, hybrid systems for MR-integrated PT (MRiPT) have not been realized so far due to a number of hitherto open technological challenges. In recent years, various research groups have started addressing these challenges and exploring the technical feasibility and clinical potential of MRiPT. The aim of this contribution is to review the different aspects of MRiPT, to report on the status quo and to identify important future research topics. METHODS: Four aspects currently under study and their future directions are discussed: modelling and experimental investigations of electromagnetic interactions between the MRI and PT systems, integration of MRiPT workflows in clinical facilities, proton dose calculation algorithms in magnetic fields, and MRI-only based proton treatment planning approaches. CONCLUSIONS: Although MRiPT is still in its infancy, significant progress on all four aspects has been made, showing promising results that justify further efforts for research and development to be undertaken. First non-clinical research solutions have recently been realized and are being thoroughly characterized. The prospect that first prototype MRiPT systems for clinical use will likely exist within the next 5 to 10 years seems realistic, but requires significant work to be performed by collaborative efforts of research groups and industrial partners. |
format | Online Article Text |
id | pubmed-7260752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72607522020-06-07 MR-guided proton therapy: a review and a preview Hoffmann, Aswin Oborn, Bradley Moteabbed, Maryam Yan, Susu Bortfeld, Thomas Knopf, Antje Fuchs, Herman Georg, Dietmar Seco, Joao Spadea, Maria Francesca Jäkel, Oliver Kurz, Christopher Parodi, Katia Radiat Oncol Review BACKGROUND: The targeting accuracy of proton therapy (PT) for moving soft-tissue tumours is expected to greatly improve by real-time magnetic resonance imaging (MRI) guidance. The integration of MRI and PT at the treatment isocenter would offer the opportunity of combining the unparalleled soft-tissue contrast and real-time imaging capabilities of MRI with the most conformal dose distribution and best dose steering capability provided by modern PT. However, hybrid systems for MR-integrated PT (MRiPT) have not been realized so far due to a number of hitherto open technological challenges. In recent years, various research groups have started addressing these challenges and exploring the technical feasibility and clinical potential of MRiPT. The aim of this contribution is to review the different aspects of MRiPT, to report on the status quo and to identify important future research topics. METHODS: Four aspects currently under study and their future directions are discussed: modelling and experimental investigations of electromagnetic interactions between the MRI and PT systems, integration of MRiPT workflows in clinical facilities, proton dose calculation algorithms in magnetic fields, and MRI-only based proton treatment planning approaches. CONCLUSIONS: Although MRiPT is still in its infancy, significant progress on all four aspects has been made, showing promising results that justify further efforts for research and development to be undertaken. First non-clinical research solutions have recently been realized and are being thoroughly characterized. The prospect that first prototype MRiPT systems for clinical use will likely exist within the next 5 to 10 years seems realistic, but requires significant work to be performed by collaborative efforts of research groups and industrial partners. BioMed Central 2020-05-29 /pmc/articles/PMC7260752/ /pubmed/32471500 http://dx.doi.org/10.1186/s13014-020-01571-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Hoffmann, Aswin Oborn, Bradley Moteabbed, Maryam Yan, Susu Bortfeld, Thomas Knopf, Antje Fuchs, Herman Georg, Dietmar Seco, Joao Spadea, Maria Francesca Jäkel, Oliver Kurz, Christopher Parodi, Katia MR-guided proton therapy: a review and a preview |
title | MR-guided proton therapy: a review and a preview |
title_full | MR-guided proton therapy: a review and a preview |
title_fullStr | MR-guided proton therapy: a review and a preview |
title_full_unstemmed | MR-guided proton therapy: a review and a preview |
title_short | MR-guided proton therapy: a review and a preview |
title_sort | mr-guided proton therapy: a review and a preview |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260752/ https://www.ncbi.nlm.nih.gov/pubmed/32471500 http://dx.doi.org/10.1186/s13014-020-01571-x |
work_keys_str_mv | AT hoffmannaswin mrguidedprotontherapyareviewandapreview AT obornbradley mrguidedprotontherapyareviewandapreview AT moteabbedmaryam mrguidedprotontherapyareviewandapreview AT yansusu mrguidedprotontherapyareviewandapreview AT bortfeldthomas mrguidedprotontherapyareviewandapreview AT knopfantje mrguidedprotontherapyareviewandapreview AT fuchsherman mrguidedprotontherapyareviewandapreview AT georgdietmar mrguidedprotontherapyareviewandapreview AT secojoao mrguidedprotontherapyareviewandapreview AT spadeamariafrancesca mrguidedprotontherapyareviewandapreview AT jakeloliver mrguidedprotontherapyareviewandapreview AT kurzchristopher mrguidedprotontherapyareviewandapreview AT parodikatia mrguidedprotontherapyareviewandapreview |